Utilizing Erythrocyte Lifespan as a Predictor for Moderate to Severe Anemia in Patients with Advanced Gastric Cancer Following Anti-Tumor Treatments: A Prospective Investigation - Takeaways - MDSpire

Utilizing Erythrocyte Lifespan as a Predictor for Moderate to Severe Anemia in Patients with Advanced Gastric Cancer Following Anti-Tumor Treatments: A Prospective Investigation

  • By

  • Xiurong Yu

  • Liyu Su

  • Rong Lu

  • Shen Zhao

  • Rongbo Lin

  • Xianren Ye

  • November 19, 2025

  • 0 min

Share

  • 1

    Gastric cancer is a leading cause of cancer-related deaths, with advanced stages often resulting in anemia due to anti-tumor treatments.

  • 2

    Erythrocyte Lifespan (ELS) is a promising predictor of anemia, reflecting the balance between red blood cell production and destruction.

  • 3

    A prospective study enrolled 56 advanced gastric cancer patients to investigate the relationship between baseline ELS and post-treatment anemia.

  • 4

    Results indicated that shorter baseline ELS correlated with lower hemoglobin levels, suggesting its potential as a predictive tool for anemia.

  • 5

    The study emphasizes the importance of early identification of anemia risk in gastric cancer patients to improve treatment outcomes and quality of life.

Original Source(s)

Utilizing Erythrocyte Lifespan as a Predictor for Moderate to Severe Anemia in Patients with Advanced Gastric Cancer Following Anti-Tumor Treatments: A Prospective Investigation

  • by Xiurong Yu, Liyu Su, Rong Lu, Shen Zhao, Rongbo Lin, Xianren Ye

  • November 19, 2025

Related Content

The impact of anemia and blood transfusion on mortality after open abdominal surgery in the elderly

Early detection and correction of preoperative anemia in patients undergoing colorectal surgery—a prospective study

Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia